The estimated Net Worth of Steven M. Friedman is at least 2.65 百万$ dollars as of 8 January 2010. Steven Friedman owns over 22,000 units of Incyte stock worth over 2,407,589$ and over the last 16 years Steven sold INCY stock worth over 239,800$.
Steven has made over 1 trades of the Incyte stock since 2010, according to the Form 4 filled with the SEC. Most recently Steven sold 22,000 units of INCY stock worth 239,800$ on 8 January 2010.
The largest trade Steven's ever made was selling 22,000 units of Incyte stock on 8 January 2010 worth over 239,800$. On average, Steven trades about 5,500 units every 0 days since 2009. As of 8 January 2010 Steven still owns at least 38,137 units of Incyte stock.
You can see the complete history of Steven Friedman stock trades at the bottom of the page.
Steven's mailing address filed with the SEC is EXPERIMENTAL STATION, ROUTE 141 AND HENRY CLAY RD, WILMINGTON, DE, 19880.
Over the last 21 years, insiders at Incyte have traded over 114,417,378$ worth of Incyte stock and bought 24,211,970 units worth 713,884,116$ . The most active insiders traders include Bros. Advisors Lp14159, L.P...、Bros. Advisors Lp667, L.P.B...、Brothers Life Sciences Capi.... On average, Incyte executives and independent directors trade stock every 14 days with the average trade being worth of 4,355,654$. The most recent stock trade was executed by Steven H Stein on 12 August 2024, trading 11,608 units of INCY stock currently worth 703,793$.
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
Incyte executives and other stock owners filed with the SEC include: